Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs.

Author: Virani, Salim S. MD, PhD; Akeroyd, Julia M. MPH; Nambi, Vijay MD, PhD; Heidenreich, Paul A. MD, MS; Morris, Pamela B. MD; Nasir, Khurram MD; Michos, Erin D. MD, MHS; Bittner, Vera A. MD, MSPH; Petersen, Laura A. MD, MPH; Ballantyne, Christie M. MD

Page: 2572-2574

http://ift.tt/2rxj6jO


http://ift.tt/2rKBHg6